S 81694

Drug Profile

S 81694

Alternative Names: NMS P153

Latest Information Update: 29 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Nerviano Medical Sciences; Servier
  • Class Antineoplastics; Small molecules
  • Mechanism of Action TTK protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Dec 2016 Servier re-initiates a phase-I trial in Solid tumours (Late-stage disease, Metastatic disease) in Netherlands and Belgium (IV) (ISRCTN35641359)
  • 24 Sep 2015 S 81694 is acquired by Servier
  • 03 Jul 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in Netherlands, Belgium (IV) (ISRCTN35641359)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top